Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company. Its news flow centers on clinical trial readouts, regulatory designations, strategic collaborations and manufacturing milestones across a broad pipeline in ophthalmology, Parkinson’s disease, radiation-induced xerostomia and other genetic medicine programs.
News updates from MeiraGTx frequently cover progress in late-stage clinical programs such as AAV-AIPL1 for Leber congenital amaurosis 4, AAV2-hAQP1 for radiation-induced xerostomia and AAV-GAD for Parkinson’s disease. The company issues releases on data presented at scientific meetings, including results from randomized, double-blind, sham-controlled studies and first-in-human trials in rare pediatric retinal dystrophies.
Investors and observers can also follow announcements about regulatory interactions, including Regenerative Medicine Advanced Therapy (RMAT) designations, orphan and Rare Pediatric Disease designations, and plans for marketing authorization applications and biologics license applications in the United States, United Kingdom and European Union. These items provide context on potential development pathways for MeiraGTx’s investigational therapies.
Another recurring theme in MeiraGTx news is strategic partnering. The company has reported a collaboration and license agreement with Eli Lilly and Company in ophthalmology, as well as a broad collaboration with Hologen AI that includes the formation of Hologen Neuro AI Ltd to advance AAV-GAD and other central nervous system programs. Updates on its relationship with Johnson & Johnson Innovative Medicine around botaretigene sparoparvovec for X-linked retinitis pigmentosa also appear in its news feed.
In addition, MeiraGTx news items highlight developments in its riboswitch gene regulation platform, promoter and capsid engineering research, and expansions of its GMP manufacturing capabilities in the United Kingdom and Ireland. Visitors to this page can review these releases to understand how MeiraGTx’s clinical, regulatory, technological and manufacturing activities evolve over time.
MeiraGTx (Nasdaq: MGTX) priced an underwritten offering of 11,111,111 ordinary shares at $9.00 per share for gross proceeds of approximately $100 million. All shares are being sold by the company; the offering is expected to close on or about April 17, 2026.
The company said net proceeds, together with existing cash, are expected to fund operations and potential commercial launches of bota-vec and AAV-hAQP1 into the second half of 2028. BofA Securities and Goldman Sachs are joint bookrunners; Raymond James is co-manager.
MeiraGTx (Nasdaq: MGTX) agreed to acquire botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for X-linked retinitis pigmentosa (XLRP), paying a $25 million upfront cash payment plus a one-time U.S. regulatory/commercial milestone and a high double-digit global royalty starting mid-2029.
The company completed CMC PPQ, holds commercial manufacturing licenses, has several hundred vials ready, and intends to file BLA/MAA in the U.S., EU and Japan aiming for a potential 2027 launch. Phase 3 LUMEOS showed strong secondary endpoints and functional vision gains despite the primary maze endpoint not meeting significance.
MeiraGTx (NASDAQ: MGTX) reported positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for grade 2/3 late radiation-induced xerostomia on April 16, 2026. The full 36-month dataset shows PRO XQ symptom improvements and unstimulated whole saliva flow increases maintained through three years, with AAV-hAQP1 described as safe and well tolerated across doses. Management highlighted one-time in-office dosing, durability of responses, and plans for a data presentation webcast on April 16, 2026.
MeiraGTx (NASDAQ: MGTX) will present 3-year data from the open-label Phase 1 AQUAx study of AAV-hAQP1 for treatment of persistent grade 2/3 radiation-induced xerostomia on April 16, 2026 at 8:00 a.m. ET.
The presentation includes cohort-level and individual patient data for PRO Xerostomia Questionnaire (XQ) and objective Unstimulated Whole Saliva Flow Rate (UWSFR) out to three years for bilateral and unilateral cohorts, an investigator discussion of disease burden and treatment administration, commercial opportunity commentary, and a Q&A. A live webcast and replay will be available on the company investor website.
MeiraGTx (Nasdaq: MGTX) announced FDA Breakthrough Therapy Designation for AAV2-hAQP1 to treat Grade 2–3 radiation-induced xerostomia, aligned Phase 2 AQUAx2 endpoints to support a potential BLA in H1 2027 and targeted US launch in early 2028. The company reported year-end cash of $68.2M, license revenue of $75M from Lilly, and a 2025 net loss of $114.2M (−$1.42/share).
Strategic deals include a $200M upfront Hologen joint venture payment, a $75M Lilly upfront, plus potential milestones and manufacturing agreements with J&J for bota-vec.
ZipBio and MeiraGTx (Nasdaq: MGTX) signed an exclusive license agreement to advance ZipBio's first-in-class AAV gene therapy programs for Geographic Atrophy targeting the complement pathway. The deal grants MeiraGTx exclusive rights and includes upfront plus potential milestone and royalty payments; financial terms were not disclosed. The collaboration pairs ZipBio's COMPACT™ AI-designed protein therapeutics with MeiraGTx's vector design, clinical development, and in-house manufacturing capabilities, while ZipBio focuses its internal efforts on immunology and cardiovascular programs.
Graviton Bioscience (NASDAQ:MGTX) will present selective ROCK2 obesity data at the 8th Annual Evercore HealthCONx Conference on December 2, 2025 at 8:45 AM ET. CEO Samuel Waksal will lead a fireside chat covering Graviton's obesity program and its selective ROCK2 inhibitor, GV101.
Key points to be discussed include:
- Target biology: ROCK2 roles in fibrosis, inflammation, cytoskeletal mechanics, and adipose tissue.
- Preclinical efficacy: GV101 reduced lipid droplets in mouse and human adipocytes and produced weight loss in rodent models with lean mass preservation.
- Clinical significance: GV101 appears to sustain fat loss while preserving muscle.
The presentation will be webcast and open to media, investors, and the public.
MeiraGTx (Nasdaq: MGTX) reported Q3 2025 results and operational updates on Nov 13, 2025. Key corporate actions include a broad ophthalmology collaboration with Eli Lilly (upfront $75.0M; >$400M in potential milestones; tiered royalties) and progress on a joint venture with Hologen (received $50.0M of $200.0M; MeiraGTx to hold 30% of JV).
Clinical/regulatory highlights: RMAT designations for AAV2-hAQP1 and AAV-GAD, AQUAx2 pivotal enrollment on track to finish end-2025 with potential BLA pathway in early 2027, and Specials program dosing for BBS10 (RPDD).
Cash: $17.1M at Sept 30, 2025; service revenue fell to $0.4M for Q3 2025 from $10.9M year-ago.
MeiraGTx (Nasdaq: MGTX) announced a broad strategic collaboration with Eli Lilly on Nov 10, 2025 to develop and commercialize genetic medicines in ophthalmology.
MeiraGTx granted Lilly worldwide exclusive rights to its AAV-AIPL1 program for LCA4 and exclusive access to in‑house intravitreal capsids, bespoke promoters (including AI‑generated promoters), and certain riboswitch technology for ocular gene editing. Clinical data reported that 11 children born legally blind gained vision after AAV-AIPL1, with additional developmental benefits described.
Financial terms include a $75 million upfront payment, eligibility for over $400 million in milestones, and tiered royalties on licensed products.
MeiraGTx (Nasdaq: MGTX) will present two posters at the ESGCT 2025 Annual Congress in Seville, Oct 7-10, 2025.
Poster P0089 reports directed evolution of novel AAV capsids from a ~1E7-variant library in non-human primate eyes, validated in human retinal organoids and iPSC-derived RPE. Selected capsids showed >2-fold higher transduction versus AAV2.7m8 and higher retinal expression in mouse intravitreal studies, supporting ocular gene therapy applications.
Poster P0170 describes scale-up of a perfusion-based AAV manufacturing process to 40L bioreactors. Bench optimization delivered up to +120% volumetric VG yield, ~50% lower plasmid use, and up to 2.2-fold lower cost-of-goods per dose; the work focuses on translating these parameters to 40L while preserving quality.